title: Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
abstract: BACKGROUND
  Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment.
  
  
  METHODS
  The models were built using population modelling software NONMEM VII based on data from two clinical studies of SCA adult patients receiving 500-2000 mg of HU once daily. Fetal hemoglobin percentage (HbF%) and mean corpuscular volume (MCV) were used as biomarkers for response. A sequential modelling approach was applied. Models were evaluated using simulation-based techniques. Comparisons of two dosing regimens were performed by simulating 10000 patients in each arm during 12 months.
  
  
  RESULTS
  The PK profiles were described by a bicompartmental model. The median (and interindividual coefficient of variation (CV)) of clearance was 11.6 L/h (30%), the central volume was 45.3 L (35%). PK steady-state was reached in about 35 days. For a given dosing regimen, HU exposure varied approximately fivefold among patients. The dynamics of HbF% and MCV were described by turnover models with inhibition of elimination of response. In the studied range of drug exposures, the effect of HU on HbF% was at its maximum (median Imax was 0.57, CV was 27%); the effect on MCV was close to its maximum, with median value of 0.14 and CV of 49%. Simulations showed that 95% of the steady-state levels of HbF% and MCV need 26 months and 3 months to be reached, respectively. The CV of the steady-state value of HbF% was about 7 times larger than that of MCV. Simulations with two different dosing regimens showed that continuous dosing led to a stronger HbF% increase in some patients.
  
  
  CONCLUSIONS
  The high variability of response to HU was related in part to pharmacokinetics and to pharmacodynamics. The steady-state value of MCV at month 3 is not predictive of the HbF% value at month 26. Hence, HbF% level may be a better biomarker for monitoring HU treatment. Continuous dosing might be more advantageous in terms of HbF% for patients who have a strong response to HU.
  
  
  BACKGROUND
  The clinical studies whose data are analysed and reported in this work were not required to be registered in France at their time. Both studies were approved by local ethics committees (of Mondor Hospital and of Kremlin-Bicetre Hospital) and written informed consent was obtained from each patient.
authors: Université de Lyon, Lyon, France.
authors: Ines
authors: I
authors: Paule
authors: Hind
authors: H
authors: Sassi
authors: Anoosha
authors: A
authors: Habibi
authors: Kim Pd
authors: KP
authors: Pham
authors: Dora
authors: D
authors: Bachir
authors: Frédéric
authors: F
authors: Galactéros
authors: Pascal
authors: P
authors: Girard
authors: Anne
authors: A
authors: Hulin
authors: Michel
authors: M
authors: Tod
references: Haematologica. 2006 Dec;91(12):1685-8
references: 17145606
references: J Pharmacokinet Pharmacodyn. 2001 Oct;28(5):481-504
references: 11768292
references: J Pharmacokinet Biopharm. 1998 Aug;26(4):385-408
references: 10214559
references: Pharmacogenomics J. 2007 Dec;7(6):386-94
references: 17299377
references: Nephron. 1976;16(1):31-41
references: 1244564
references: Blood. 2003 Jul 1;102(1):365-70
references: 12609840
references: Blood. 2011 Feb 10;117(6):e57-66
references: 21135259
references: Ann Intern Med. 2008 Jun 17;148(12):939-55
references: 18458272
references: Hematol Oncol Clin North Am. 2005 Oct;19(5):975-87, ix
references: 16214656
references: Br J Haematol. 2008 Apr;141(2):254-9
references: 18318767
references: Clin Pharmacokinet. 1998 May;34(5):347-58
references: 9592619
references: N Engl J Med. 1990 Apr 12;322(15):1037-45
references: 1690857
references: Science. 1997 Apr 4;276(5309):122-6
references: 9082983
references: Br J Clin Pharmacol. 2004 Aug;58(2):119-33
references: 15255794
references: JAMA. 2003 Apr 2;289(13):1645-51
references: 12672732
references: Pharm Res. 2006 Sep;23(9):2036-49
references: 16906454
references: Hemoglobin. 2007;31(4):417-25
references: 17994375
references: Nature. 2003 Apr 24;422(6934):835-47
references: 12695777
references: AAPS J. 2011 Jun;13(2):143-51
references: 21302010
references: N Engl J Med. 2008 Mar 27;358(13):1362-9
references: 18367739
references: Blood. 2010 Sep 23;116(12):2152-9
references: 20566895
references: Blood. 2005 Nov 1;106(9):3256-63
references: 15985540
references: N Engl J Med. 1995 May 18;332(20):1317-22
references: 7715639
references: J Clin Invest. 2003 Jan;111(2):231-9
references: 12531879